Teva shared that the Food and Drug Administration has accepted, and the European Medicines Agency has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s Prolia (denosumab). Both ...
Amgen Inc. moved to a key stage for its potential blockbuster drug denosumab on Monday when the Food and Drug Administration announced that a panel would review the drug, which is an experimental ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and ...
Clinical data from a phase 3 trial show Ponlimsi has comparable safety and efficacy to Prolia in women with postmenopausal osteoporosis. The Food and Drug Administration (FDA) has approved Ponlimsi ™ ...
Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the approval of AVT03, a proposed biosimilar of Amgen’s AMGN Prolia (denosumab) ...
Please provide your email address to receive an email when new articles are posted on . Denosumab as a first-line osteoporosis therapy is linked to lower fracture risks than alendronate among ...
--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results